Project Grant R61AI187100
Award Date
12/27/24
Completion Date
11/30/27
Dollars Obligated
$267K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Cambodia
Similar Awards
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to establish continuous, high-yield culture systems for the asexual stages of the Plasmodium vivax (P. vivax) malaria parasite. The primary objectives are to (1) develop P. vivax strains that can robustly invade reticulocytes (immature red blood cells) in culture and (2) improve P. vivax development in vitro by...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $406,450.00 to support research by Harvard T.H. Chan School of Public Health focused on establishing continuous in vitro culture and genetic methods for the malaria parasite Plasmodium vivax. The key objectives are to: (1) optimize the production of reticulocytes (young red blood cells) to support the growth of P....
This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $800,470 to Mahidol University in Thailand to conduct research on the epidemiology and vector biology of human and zoonotic malaria in Southeast Asia. The research program consists of two interdependent projects: Project 1 examines malaria parasite distribution and transmission dynamics in human populations,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $813,160 Project Grant (CFDA 93.855 Allergy and Infectious Diseases Research) to George Washington University to develop mRNA-LNP vaccines targeting multiple stages and species of the human malaria parasite. The research aims to evaluate protective efficacy of vaccine antigens individually and in combination for both Plasmodium falciparum and Plasmodium vivax malaria, with studies planned in mice and non-human...
The National Institute of Allergy and Infectious Diseases (NIAID), through the Allergy and Infectious Diseases Research program (CFDA 93.855), has awarded a $427,000 Project Grant (R61AI187095) to the New York Blood Center, Inc. to establish a continuous in vitro culture system for the propagation of the Babesia microti parasite in human red blood cells. The primary objectives of this research are to identify the specific host red blood cell subpopulations and culture conditions that enable...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $479,204 Project Grant (CFDA 93.855) to the University of Maryland, Baltimore to conduct research on parasite variant surface antigens and their role in severe malaria. The 2-year project, titled "Parasite Variant Surface Antigen Expression and Immune Gaps in Severe Malaria," aims to identify parasite genes associated with severe malaria in order to inform the development of vaccines or therapeutics. The...
This $676,425 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the mechanisms by which the Plasmodium falciparum parasite causes neutrophil dysfunction during malaria infection. The research team at The Washington University aims to identify how the parasite's secreted histidine-rich protein II (HRPII) impairs the oxidative burst activity of neutrophils, a...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $924,000 in funding to Tufts University School of Medicine. The award aims to support research focused on mitigating the adhesion of Plasmodium falciparum-infected red blood cells to endothelial cells, a key factor in the development of severe and often fatal cerebral malaria. The research project will...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to discover targets of naturally acquired immunity against severe Plasmodium falciparum malaria and develop them as novel blood-stage vaccine candidates. The $708,202 grant, awarded to Brown University on December 20, 2024, will support a case-control study in a malaria-endemic region of western Kenya to identify...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $153,056 to The Washington University in St. Louis to conduct research on heme homeostasis in the malaria parasite Plasmodium falciparum. The research aims to identify parasite proteins involved in maintaining cytosolic heme concentrations and investigate the role of the heme detoxification protein PfHDP in heme...